Low Plasma Apelin Levels in Newly Diagnosed Type 2 Diabetes Mellitus

Abstract

Objective: To investigate blood apelin concentrations in patients with newly diagnosed and untreated type 2 diabetes mellitus (T2DM) who had no additional disorder and to investigate the association of apelin with adiponectin, body mass indexes (BMI) and insulin sensitivity.

Methods: Forty patients with T2DM and 40 healthy controls were enrolled. Apelin levels were measured along with BMI, lipids, glucose, insulin and adiponectin levels, and HOMA-IR indexes. Age, sex and BMI were similar in the two groups.

Results: Plasma apelin and adiponectin levels were significantly lower in the diabetic group compared to controls (p<0.001, for both). Insulin levels and HOMA indexes were significantly higher in patients with T2DM (p<0.001 and p=0.001, respectively). Apelin levels were negatively correlated with age (r=-0.315, p=0.006), fasting blood glucose (r=-0.556, p<0.001) and HOMA indexes (r=-0.411, p=0.001), and positively correlated with plasma adiponectin levels (r=0.593, p<0.001). Plasma adiponectin was negatively correlated to plasma insulin (r=-0.379, p=0.001), fasting glucose (r=-0.604, p<0.001), HOMA-IR (r=-0.559, p<0.001) and BMI (=-0.229, p=0.04).

Conclusions: Plasma apelin is reduced in newly diagnosed and untreated patients with T2DM having no confounders. Regulation of circulating apelin and adiponectin seems to be in the same manner in patients with T2DM. Dysregulation of apelin might be involved in the mechanism of establishment of overt diabetes mellitus as well as associated atherosclerotic complications.

apelin - type 2 diabetes mellitus

References

• 1 Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation.  Diabet Med. 1998;  15 539-553
• 2 Boso M, Emanuele E, Politi P, Pace A, Arra M, Ucelli di Nemi S. et al . Reduced plasma apelin levels in patients with autistic spectrum disorder.  Arch Med Res. 2007;  38 70-74
• 3 Boucher J, Masri B, Daviaud D, Gesta S, Guigne C, Mazzucotelli A. et al . Apelin, a newly identified adipokine up-regulated by insulin and obesity.  Endocrinology. 2005;  146 1764-1771
• 4 Cheng X, Cheng XS, Pang CC. Venous dilator effect of apelin, an endogenous peptide ligand for the orphan APJ receptor, in conscious rats.  Eur J Pharmacol. 2003;  470 171-175
• 5 Chong KS, Gardner RS, Morton JJ, Ashley EA, MacDonagh TA. Plasma concentrations of the novel peptide apelin are decreased in patients with chronic heart failure.  Eur J Heart Fail. 2006;  8 355-360
• 6 Codognotto M, Piccoli A, Zaninotto M, Mion M, Vertolli U, Tona F. et al . Evidence for decreased circulating apelin beyond heart involvement in uremic cardiomyopathy.  Am J Nephrol. 2007;  27 1-6
• 7 Daviaud D, Boucher J, Gesta S, Dray C, Guigne C, Quilliot D. TNFalpha up-regulates apelin expression in human and mouse adipose tissue.  FASEB J. 2006;  20 1528-1530
• 8 Dogru T, Sonmez A, Tasci I, Bozoglu E, Yilmaz MI, Genc H. et al . Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerance.  Diabetes Res Clin Pract. 2007;  76 24-29
• 9 Ellinor PT, Low AF, Macrae CA. Reduced apelin levels in lone atrial fibrillation.  Eur Heart J. 2006;  27 222-226
• 10 Fernandez-Real JM, Botas-Cervero P, Lopez-Bermano A, Casamitjana R, Funahashi T, Delgado E. Adiponectin is independently associated with glycosylated haemoglobin.  Eur J Endocrinol. 2004;  150 201-205
• 11 Foldes G, Horkay F, Szokodi I, Vuolteenaho O, Ilves M, Lindstedt KA. et al . Circulating and cardiac levels of apelin, the novel ligand of the orphan receptor APJ, in patients with heart failure.  Biochem Biophys Res Commun. 2003;  308 480-485
• 12 Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.  Clin Chem. 1972;  18 499-502
• 13 Goetze JP, Rehfeld JF, Carlsen J, Videbaek R, Andersen CB, Boesgaard S. et al . Apelin: a new plasma marker of cardiopulmonary disease.  Regul Pept. 2006;  15 133-134
• 14 Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, Howard BV. et al . Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association.  Circulation. 1999;  100 1134-1146
• 15 Heinonen MV, Purhonen AK, Miettinen P, Paakkonen M, Pirinen E, Alhava E. et al . Apelin, orexin-A and leptin plasma levels in morbid obesity and effect of gastric banding.  Regul Pept. 2005;  130 7-13
• 16 Higuchi K, Masaki T, Gotoh K, Chiba S, Katsuragi I, Tanaka K. et al . Apelin, an APJ receptor ligand, regulates body adiposity and favors the mRNA expression of uncoupling proteins in mice.  Endocrinology. 2007;  148 2622-2629
• 17 Kasai A, Shintani N, Oda M, Kakuda M, Hashimoto H, Matsuda T. et al . Apelin is a novel angiogenic factor in retinal endothelial cells.  Biochem Biophys Res Commun. 2004;  325 395-400
• 18 Kleinz MJ, Davenport AP. Immunocytochemical localization of the endogenous vasoactive peptide apelin to human vascular and endocardial endothelial cells.  Regul Pept. 2004;  118 119-125
• 19 Lee DK, Cheng R, Nguyen T, Fan T, Kariyawasam AP, Liu Y. et al . Characterization of apelin, the ligand for the APJ receptor.  J Neurochem. 2000;  74 34-41
• 20 Lee DK, Saldivia VR, Nguyen T, Cheng R, George SR, O’Dowd BF. Modification of the terminal residue of apelin-13 antagonizes its hypotensive action.  Endocrinology. 2005;  146 231-236
• 21 Li L, Yang G, Li Q, Tang Y, Yang M, Yang H. et al . Changes and relations of circulating visfatin, apelin, and resistin levels in normal, impaired glucose tolerance, and type 2 diabetic subjects.  Exp Clin Endocrinol Diabetes. 2006;  114 544-548
• 22 Małyszko J, Małyszko JS, Koźminski P, Myśliwiec M. Apelin and cardiac function in hemodialyzed patients: possible relations?.  Am J Nephrol. 2006;  26 121-126
• 23 Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man.  Diabetologia. 1985;  28 412-419
• 24 O’Shea M, Hansen MJ, Tatemoto K, Morris MJ. Inhibitory effect of apelin-12 on nocturnal food intake in the rat.  Nutr Neurosci. 2003;  6 163-167
• 25 Reaux-Le Goazigo A, Alvear-Perez R, Zizzari P, Epelbaum J, Bluet-Pajot MT, Llorens-Cortes C. Cellular localization of apelin and its receptor in the anterior pituitary: evidence for a direct stimulatory action of apelin on ACTH release.  Am J Physiol Endocrinol Metab. 2007;  292 7-15
• 26 Sorhede Winzell M, Magnusson C, Ahren B. The apj receptor is expressed in pancreatic islets and its ligand, apelin, inhibits insulin secretion in mice.  Regul Pept. 2005;  131 12-17
• 27 Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men.  JAMA. 2004;  291 1730-1737
• 28 Reusch J, Boris B, Draznin BB. Atherosclerosis in diabetes and insulin resistance.  Diabetes Obes Metab. 2007;  9 455-463
• 29 Riera-Guardia N, Rothenbacher D. The effect of thiazolidinediones on adiponectin serum level: a meta-analysis.  Diabetes Obes Metab. 2007;  , (in press) (DOI: 10.1111/j.1463-1326.2007.00755.x).
• 30 Schinner S, Scherbaum WA, Bornstein SR, Barthel A. Molecular mechanisms of insulin resistance.  Diabet Med. 2005;  22 674-682
• 31 Szokodi I, Tavi P, Foldes G, Voutilainen-Myllyla S, Ilves M, Tokola H. et al . Apelin, the novel endogenous ligand of the orphan receptor APJ, regulates cardiac contractility.  Circ Res. 2002;  91 434-440
• 32 Tasci I, Dogru T, Naharci I, Erdem G, Yilmaz MI, Sonmez A. et al . Plasma apelin is lower in patients with elevated LDL-cholesterol.  Exp Clin Endocrinol Diabetes. 2007;  7 428-432
• 33 Tatemoto K, Hosoya M, Habata Y, Fujii R, Kakegawa T, Zou MX. et al . Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor.  Biochem Biophys Res Commun. 1998;  251 471-476
• 34 Tatemoto K, Takayama K, Zou MX, Kumaki I, Zhang W, Kumano K. et al . The novel peptide apelin lowers blood pressure via a nitric oxide-dependent mechanism.  Regul Pept. 2001;  99 87-92
• 35 Gaal LF Van, Mertens IL, Block CE De. Mechanisms linking obesity with cardiovascular disease.  Nature. 2006;  444 875-880
• 36 Xie H, Yuan LQ, Luo XH, Huang J, Cui RR, Guo LJ. et al . Apelin suppresses apoptosis of human osteoblasts.  Apoptosis. 2007;  12 247-254
• 37 Zhong JC, Yu XY, Huang Y, Yung LM, Lau CW, Lin SG. Apelin modulates aortic vascular tone via endothelial nitric oxide synthase phosphorylation pathway in diabetic mice.  Cardiovasc Res. 2007;  74 388-395

Correspondence